KBC Group
BBIO icon

KBC Group’s BridgeBio Pharma BBIO Stock Holding History

KBC Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Hold
4,743
– – ﹤0.01% 865
2026
Q1 		$352K Buy
4,743
+548
+13% +$39.7K ﹤0.01% 840
2025
Q4 		$321K Hold
4,195
– – ﹤0.01% 781
2025
Q3 		$218K Hold
4,195
– – ﹤0.01% 871
2025
Q2 		$181K Sell
4,195
-1,905
-31% -$69.3K ﹤0.01% 905
2025
Q1 		$211K Buy
6,100
+153
+3% +$5.16K ﹤0.01% 1038
2024
Q4 		$163K Buy
5,947
+2,456
+70% +$63.5K ﹤0.01% 1247
2024
Q3 		$89K Buy
3,491
+649
+23% +$17K ﹤0.01% 1359
2024
Q2 		$72K Hold
2,842
– – ﹤0.01% 1386
2024
Q1 		$88K Buy
2,842
+887
+45% +$30.2K ﹤0.01% 1190
2023
Q4 		$79K Sell
1,955
-256
-12% -$7.69K ﹤0.01% 1209
2023
Q3 		$58K Buy
+2,211
New +$62.7K ﹤0.01% 1322

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

KBC Group's BBIO Position: Q2 2026 in Review

KBC Group held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 4,743 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

KBC Group first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • KBC Group held 4,743 shares of BridgeBio Pharma worth $353K as of Q2 2026.
  • KBC Group left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #865 holding.
  • KBC Group first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.